ReproCELL Inc. (JP:4978)

:4978

4978

ReproCELL Inc.

RESEARCH TOOLSreports

ReproCELL Inc. (4978) Price & Analysis

Compare

0 Followers

4978 Stock Chart & Stats

¥143.00

¥3.00(2.91%)

At close: Jan 08 4:00 PM EST

¥143.00

¥3.00(2.91%)

Day’s Range― - ―

52-Week Range¥112.00 - ¥242.00

Previous CloseN/A

Volume331.50K

Average Volume (3M)510.74K

Market Cap

¥16.74B

Enterprise Value¥14.02B

Total Cash (Recent Filing)¥4.72B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)120.8

Beta0.57

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.29

Shares Outstanding95,147,890

10 Day Avg. Volume504,660

30 Day Avg. Volume510,736

Financial Highlights & Ratios

PEG Ratio-0.33

Price to Book (P/B)1.52

Price to Sales (P/S)4.58

P/FCF Ratio-169.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low Debt / Strong Balance SheetEffectively zero debt and growing equity provide durable financial flexibility. This lowers solvency risk, supports multi-year R&D or product development spend, and preserves optionality for partnerships or M&A without stressing liquidity, a structural advantage over leveraged peers.

Profitability Inflection & Margin ExpansionA turning point to positive net income and a large gross margin improvement indicate improving unit economics and better pricing or cost structure on core products. If sustained, higher gross margins provide room to invest in scale while moving toward operating profitability over the medium term.

Recurring Consumables And Services Revenue ModelA business built on repeat consumables and contract services creates recurring demand tied to lab throughput. This structural revenue mix improves predictability and customer stickiness over time versus one-off product sales, supporting steady long-term revenue if market adoption of iPSC workflows continues.

Bears Say

Weak Cash Generation / Negative Free Cash FlowPersistent negative free cash flow despite a small positive operating cash flow means earnings are not converting to cash reliably. This constrains ability to self-fund growth, increases reliance on external financing or equity, and limits durable reinvestment capacity over the next several quarters.

Operating Profit Still NegativeEven with net income improvement and higher gross margins, persistent operating losses show that overhead and operating expenses outpace core gross profit. Until operating profitability is achieved, structural leverage to growth is limited and margin sustainability remains uncertain.

Uneven Revenue Growth And Low ReturnsVolatile top-line trends and very low return on equity indicate inconsistent demand and low capital efficiency. This heightens execution risk: management must sustain revenue momentum and improve returns to deliver durable shareholder value over a multi-quarter horizon.

4978 FAQ

What was ReproCELL Inc.’s price range in the past 12 months?

ReproCELL Inc. lowest stock price was ¥112.00 and its highest was ¥242.00 in the past 12 months.

What is ReproCELL Inc.’s market cap?

ReproCELL Inc.’s market cap is ¥16.74B.

When is ReproCELL Inc.’s upcoming earnings report date?

ReproCELL Inc.’s upcoming earnings report date is May 20, 2026 which is in 55 days.

How were ReproCELL Inc.’s earnings last quarter?

ReproCELL Inc. released its earnings results on Feb 12, 2026. The company reported ¥0.29 earnings per share for the quarter, beating the consensus estimate of N/A by ¥0.29.

Is ReproCELL Inc. overvalued?

According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ReproCELL Inc. pay dividends?

ReproCELL Inc. does not currently pay dividends.

What is ReproCELL Inc.’s EPS estimate?

ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ReproCELL Inc. have?

ReproCELL Inc. has 95,147,890 shares outstanding.

What happened to ReproCELL Inc.’s price movement after its last earnings report?

ReproCELL Inc. reported an EPS of ¥0.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.829%.

Which hedge fund is a major shareholder of ReproCELL Inc.?

Currently, no hedge funds are holding shares in JP:4978

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ReproCELL Inc.

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.